StreetAlpha.app
Home › Stocks › EWTX

Edgewise Therapeutics, Inc. (EWTX)

Healthcare
$39.91
▼ −3.07%
LAST CLOSE · NOV 20

Edgewise Therapeutics develops small molecule medicines for rare muscle diseases, based in Boulder, Colorado. It last closed at $39.91 on Nov 20, down 3.07% on the day. The next earnings report for EWTX is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, EWTX reported EPS of $9.65. Over its last 8 reports the stock moved an average of 2.5% the session after earnings. Over the last 12 months EWTX insiders bought $0 of stock on the open market and sold $17.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is EWTX in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold EWTX.

Key Stats

Last 12 months
Results
Net income
$1.0B
EPS (diluted)
$8.38
Free cash flow
−$202.3M
Valuation
Market cap
$4.4B
109.5M shares
P/E
4.8
Price over 12 month EPS
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$68.7M
At Sep 30
Shareholder equity
$1.6B
Shares outstanding
109.5M
At Oct 31
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$42.8M−$42.8MFY2021FY2022: −$67.6M−$67.6MFY2022FY2023: −$100.2M−$100.2MFY2023FY2024: −$133.8M−$133.8MFY2024FY2025: −$167.8M−$167.8MFY2025

From EWTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
$9.65
Quarter ended Sep 2026
Year ago EPS
-$0.39
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.42Dec '24Mar 2025: -$0.43Mar '25Jun 2025: -$0.34Jun '25Sep 2025: -$0.39Sep '25Dec 2025: -$0.48Dec '25Mar 2026: -$0.46Mar '26Jun 2026: -$0.53Jun '26Sep 2026: $9.65Sep '26Latest $9.65
Revenue by quarter
Not enough quarters on file yet.
How EWTX moved after its last 8 reports
Average move the session after a report ±2.5%
Nov 4, 2026After the close+3.6%
Aug 6, 2026Time not announced−1.3%
May 7, 2026Time not announced−3.8%
Feb 26, 2026Time not announced−1.5%
Nov 6, 2025Time not announced−1.6%
Aug 7, 2025Time not announced−4.2%
May 8, 2025Time not announced+1.2%
Mar 3, 2025Time not announced−2.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on EWTXStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on EWTX
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on EWTX

Technical Analysis

EWTX · as of the Nov 20 close · updated each morning
Pullback inside a longer uptrend

The stock is 5% below its 20 day and 3% below its 50 day average. It is 6% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the Pivot S1 at $39.27, and the nearest resistance the Pivot at $40.34.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityHigh, 6.6%/day
Key levels
$48.7852 week high+22.2%
$41.8520 day average+4.9%
$41.81100 day average+4.8%
$41.1450 day average+3.1%
$40.97Pivot R1+2.7%
$40.77Swing high (Jun 1)+2.2%
$40.34Pivot+1.1%
$39.91Last close
$39.27Pivot S1−1.6%
$38.51Swing low (Sep 29)−3.5%
$37.34200 day average−6.4%
$19.7652 week low−50.5%
Indicators
RSI (14)44.19Middle of its rangeNeutral
MACD0.52Below its signal lineBearish
Stochastic34.1Middle of its rangeNeutral
ADX (14)18.3No clear trend
Williams %R-73.5Oversold below −80, overbought above −20Neutral
CCI (20)-36.6Oversold below −100, overbought above 100Neutral
Rate of change−11.4%Change over 10 sessionsBearish
ATR (14)$2.63Typical daily range, 6.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for EWTX

What happened before

See how EWTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow EWTX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How EWTX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for EWTXHow many large options trades hit EWTX, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

EWTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲146 buying vs 92 selling
  • ▲Held by funds +6.3 pts
  • ▲Funds holding +27
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding253226+11.9%
In funds' top 101513+15.4%
Held by funds115.3%108.9%+6.3 pts
New / increased46 / 10040 / 82+19.7%
Reduced / sold out71 / 2173 / 26−7.1%
Put/call ratio0.870.49+77.1%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See EWTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

EWTX Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$17.6M13 sales · 7 insiders
76% of the selling was under pre-arranged trading plans.
2026-01 sold $3.4M2026-03 sold $1.2M2026-04 sold $926K2026-05 sold $2.1M2026-07 sold $7.9M2026-08 sold $1.9M2026-11 sold $241KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 16Joanne M. DonovanCmoSale plan854$45.48$39K
Nov 10Michael NofiCFOSale4,442$45.43$202K
Aug 13Joanne M. DonovanCmoSale9,441$43.71$413K
Aug 12Kevin KochPresident and CEOSale17,971$43.68$785K
Aug 12John R MooreGeneral CounselSale5,016$43.82$220K
Aug 12Behrad DerakhshanChief Business OfficerSale5,100$43.81$223K
Every insider buy and sale for EWTX over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See EWTX insider trades →

From SEC Form 4 filings by EWTX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether EWTX is in one of them and how their past EWTX trades turned out.

EWTX in the AI portfolios
Loading…

EWTX News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered EWTX in an article yet. Here's the latest on the wider market.

EWTX in the news

About Edgewise Therapeutics

Edgewise Therapeutics is a biopharmaceutical company based in Boulder, Colorado, that develops small molecule medicines for serious muscle diseases. Its main candidates target rare muscular dystrophies, including Duchenne and Becker, and a heart condition called hypertrophic cardiomyopathy. The company uses its own drug discovery platform to find treatments that act on muscle tissue, and these candidates are still in clinical trials. It is developing the therapies for patients with these conditions and the physicians who treat them.

Headquarters
Boulder, CO